Phase 1 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have one of the following cancers that cannot be surgically removed, has spread to other parts of the body, or is locally advanced: liver cancer (hepatocellular carcinoma) at a certain stage or that has not responded to other local treatments; stomach cancer that produces a protein called AFP (confirmed by blood test or tissue test); germ cell tumors, including certain types found outside the reproductive organs (such as in the chest, brain, or abdomen), where no further curative treatment options exist; or a specific type of lung cancer (squamous non-small cell lung cancer) that tests positive for a protein called GPC3 and has previously been treated with a type of immunotherapy called a checkpoint inhibitor.
- People who have at least one tumour that can be assessed or measured on scans, as defined by standard medical criteria.
- People who are generally able to carry out daily activities with no more than minor limitations, based on a standard performance scale (confirm with trial site).
- People whose liver, kidneys, and other organs are functioning adequately, as defined in the trial protocol (confirm with trial site).
- People who are able to provide a sample of tumour tissue for certain parts of the study.
Who may not be able to join:
- People who have previously received any treatment specifically targeting the proteins GPC3 or 4-1BB (CD137).
- People who have cancer that has spread to the lining around the brain or spinal cord, or who have brain metastases that have not been treated or are not under control.
- People who have an active autoimmune disease, or a history of autoimmune disease that could return.
- People who have been diagnosed with another type of cancer within the last 2 years — exceptions may apply for the cancer type being studied in this trial, or for a previously treated localised cancer (confirm with trial site).
- People who have needed higher-dose steroid tablets or other immune-suppressing medications within the 14 days before starting the trial.
- People with certain serious conditions affecting the lungs, heart, blood clotting, or who have active infections, as defined in the trial protocol (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Director, BeOne Medicines
Phone: 1.877.828.5568
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs); Part A and B: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-B2033; Part A and B: Recommended Phase 2 dose (RP2D) of BGB-B2033; Part C and D: Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.